Experience with ebrantil used in patients with resistant arterial hypertension in chronic kidney disease

Abstract

Summary. Aim. To evaluate the clinical efficacy of ebrantil used in patients with resistant arterial hypertension (RAH) in Stage III-V chronic kidney disease (CKD). Subjects and methods. Sixty-five patients with Stage III-V CKD and RAH (systolic blood pressure (SBP) 215.7±4.0 mm Hg and diastolic blood pressure (DBP) 114.6±2.3 mm Hg) were followed up. The patients received intravenous ebrantil (urapidil) in a dose of 25 mg for 5 days and then were switched to its oral use as 30-60-mg capsules twice daily for 12 weeks. Results. The intravenous infusion caused a significant fall in SBP and DBP by 23.6 and 16.7%, respectively, within 60-90 min. A steady-state antihypertensive effect was achieved on days 5-7 (SBP and DBP was lowered to 146.8±6.1 and 95.6±5.3 mm Hg, respectively; p

Keywords

• resistant arterial hypertension
• chronic kidney disease
• ebrantil